Compare · CRON vs VLON
CRON vs VLON
Side-by-side comparison of Cronos Group Inc. (CRON) and Vallon Pharmaceuticals Inc. (VLON): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CRON and VLON operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- CRON is the larger of the two at $1.27B, about 41.8x VLON ($30.3M).
- CRON has hit the wire 3 times in the past 4 weeks while VLON has been quiet.
- CRON has more recent analyst coverage (11 ratings vs 1 for VLON).
- Company
- Cronos Group Inc.
- Vallon Pharmaceuticals Inc.
- Price
- $2.68+3.47%
- $12.00+2453.19%
- Market cap
- $1.27B
- $30.3M
- 1M return
- +2.29%
- -
- 1Y return
- +46.45%
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 3
- 0
- Recent ratings
- 11
- 1
Cronos Group Inc.
Cronos Group Inc. operates as a cannabinoid company. It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through e-commerce, retail, and hospitality partner channels under the Lord Jones and Happy Dance brands in the United States. The company is also involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. It sells cannabis and cannabis products, including dried cannabis, pre-rolls, and cannabis extracts through wholesale and direct-to-client channels under its wellness platform, PEACE NATURALS; and operates under two adult-use brands, COVE and Spinach. The company also exports dried cannabis and cannabis oils to Germany, Israel, and Australia. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.
Vallon Pharmaceuticals Inc.
Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of prescription drugs for central nervous system disorders. The company develops abuse-deterrent amphetamine immediate-release, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder and narcolepsy. It also develops ADMIR, an abuse deterrent formulation of Ritalin. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania.
Latest CRON
- SEC Form DEFA14A filed by Cronos Group Inc.
- SEC Form DEF 14A filed by Cronos Group Inc.
- Cronos Group Inc. to Hold 2026 First Quarter Earnings Conference Call on May 11, 2026
- SEC Form 4 filed by Shlimak Anna
- Officer Doucet Terrence Gregory Joseph converted options into 23,897 shares and covered exercise/tax liability with 12,276 shares, increasing direct ownership by 12% to 105,190 units (SEC Form 4)
- Officer Weigensberg Arye converted options into 24,236 shares, increasing direct ownership by 13% to 208,437 units (SEC Form 4)
- Officer Gorenstein Michael Ryan converted options into 324,540 shares and covered exercise/tax liability with 127,706 shares, increasing direct ownership by 2% to 13,213,017 units (SEC Form 4)
- Officer Shlimak Anna converted options into 45,226 shares and covered exercise/tax liability with 16,354 shares, increasing direct ownership by 9% to 339,933 units (SEC Form 4)
- Chief Growth Officer Jacobson Jeffrey David converted options into 59,191 shares and covered exercise/tax liability with 22,552 shares, increasing direct ownership by 8% to 484,681 units (SEC Form 4)
- Officer Buggy Shannon covered exercise/tax liability with 9,202 shares and converted options into 20,938 shares, increasing direct ownership by 8% to 166,879 units (SEC Form 4)
Latest VLON
- SEC Form 424B3 filed by Vallon Pharmaceuticals Inc.
- Vallon Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- SEC Form 424B4 filed by Vallon Pharmaceuticals Inc.
- SEC Form EFFECT filed by Vallon Pharmaceuticals Inc.
- SEC Form S-1/A filed by Vallon Pharmaceuticals Inc. (Amendment)
- SEC Form S-1/A filed by Vallon Pharmaceuticals Inc. (Amendment)
- SEC Form 424B3 filed by Vallon Pharmaceuticals Inc.
- Vallon Pharmaceuticals Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- SEC Form 424B3 filed by Vallon Pharmaceuticals Inc.
- Vallon Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders